|
Site/Type |
Protocol |
| Breast Cancer |
RTOG 0517: Padiopharmaceuticals and Zoledronic acid for bone metastases
Genetech AVF4349n: Observational study of treatment patterns / safety outcomes |
| Cervix |
GOG 221: Pelvic & Para-aortic lymphadenectomy--Glycoprotein & Glycan profiling |
| Increased risk for Ovarian Cancer | GOG 215: Bone Mineral Density--Zoledronic acid versus observation for women who have risk reducing surgery that removed both ovaries
GOG 235: Study of YKL-40 in patietns with FIGO stage III or IV undergoing chemotherapy |
| Lung Cancer | CTSU S0424: Molecular epidemiology study in smokers or non smokers who have non-small cell lung cancer
RTOG 517: Radiopharmaceuticals & Soledronic acid for osteoblastic metastases |
| Nausea / Vomiting |
URCC U1902: Ginger versus Placebo for individuals receiving chemotherapy
URCC U1105: Prevention of delayed nausea for Breast cancer patients receiving Doxorubicin or Epirubicicn for the first time |
| Bone Metastases |
RTOG 517: Radiopharmaceuticals & Soledronic acid for osteoblastic metastases |
| Relaxation during chemotherapy |
MDA 2004-0024: Chemoththerapy with Mindful relaxation |
| Sleep Disturbance |
URCC U3905: Yoga for persistent sleep disturbance after treatment |
| Peripheral Neuropathy |
MDA 2004-0728: Prevention of Cisplatin or Oxaliplatin-induced peripheral neuropathy with Alphs Lipoic Acid |
| Dyspnea (shortness of breath) |
URCC U1701: Buspirone Hydrochloride versus Placebo after first cycle of chemotherapy |
| Prostate |
CTSU C90202: Early treatment with Zoledronic acid versus standard treatment with Zoledronic acid to prevent skeletal related events in men with prostate cancer metastatic to bone
RTOG 0517: Padiopharmaceuticals and Zoledronic acid for bone metastases |
Breast Cancer Clinic
